The class of C6orf106_D17Wsu92e inhibitors encompasses a diverse range of chemicals strategically targeting various cellular pathways to indirectly regulate the function of this enigmatic protein. Vorinostat, an HDAC inhibitor, intricately alters chromatin structure and gene regulation, thereby influencing the epigenetic landscape associated with C6orf106_D17Wsu92e expression and function. This modulation plays a pivotal role in affecting the intricate regulatory mechanisms of C6orf106_D17Wsu92e within the cellular milieu. Proteasome inhibitor Bortezomib disrupts protein degradation, indirectly impacting C6orf106_D17Wsu92e by modulating the turnover of key regulatory proteins. The PI3 kinase inhibitor LY294002 interferes with downstream signaling pathways, affecting cellular processes linked to C6orf106_D17Wsu92e function and regulation. TGF-β receptor inhibitor SB-431542 modulates a signaling pathway potentially linked to C6orf106_D17Wsu92e's regulatory mechanisms.
Multi-kinase inhibitor Sorafenib and MEK inhibitor PD0325901 impact the RAF/MEK/ERK and MAPK pathways, respectively, indirectly influencing C6orf106_D17Wsu92e by altering signaling cascades associated with cell proliferation and survival. HDAC inhibitor VX-11e further contributes to the epigenetic modulation of C6orf106_D17Wsu92e expression. AT13148, a multi-AGC kinase inhibitor, and mTOR inhibitor AZD8055 modulate various signaling pathways, indirectly impacting C6orf106_D17Wsu92e by influencing the activity of kinases linked to its regulatory mechanisms. MEK inhibitor Trametinib alters the MAPK pathway, while JNK inhibitor SP600125 modulates stress-activated protein kinase pathways, both indirectly influencing C6orf106_D17Wsu92e by impacting relevant signaling cascades. CHK1 kinase inhibitor AZD7762 impacts cell cycle checkpoints, indirectly regulating C6orf106_D17Wsu92e and influencing processes linked to its function during cell cycle progression. This diverse array of inhibitors sheds light on potential avenues for further research into the regulatory mechanisms of C6orf106_D17Wsu92e and its intricate involvement in cellular processes, offering a comprehensive view of the intricate interplay between this protein and the complex network of signaling pathways within the cellular landscape.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC inhibitor influencing gene expression. Alters chromatin structure and gene regulation, indirectly affecting C6orf106_D17Wsu92e by modulating the epigenetic landscape associated with its expression and function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor disrupting protein degradation. Indirectly influences C6orf106_D17Wsu92e by affecting the turnover of key regulatory proteins, thereby modulating signaling cascades associated with the protein of interest. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3 kinase inhibitor impacting cell survival and proliferation. Indirectly affects C6orf106_D17Wsu92e through interference with downstream signaling pathways that regulate its function and contribute to cellular processes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β receptor inhibitor influencing TGF-β signaling. Indirectly modulates C6orf106_D17Wsu92e by disrupting a signaling pathway that may be linked to its regulatory mechanisms. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Multi-kinase inhibitor affecting RAF/MEK/ERK pathway. Indirectly impacts C6orf106_D17Wsu92e by altering the activity of signaling cascades related to cell proliferation and survival. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
HDAC inhibitor influencing gene expression. Indirectly affects C6orf106_D17Wsu92e through modulation of chromatin structure and gene regulation, impacting the protein's expression and function. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
mTOR inhibitor affecting protein synthesis and cell growth. Indirectly impacts C6orf106_D17Wsu92e through modulation of cellular processes linked to its function and regulation. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor influencing the MAPK pathway. Indirectly modulates C6orf106_D17Wsu92e by altering the activity of signaling cascades associated with cell proliferation and survival. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting stress-activated protein kinase pathways. Indirectly influences C6orf106_D17Wsu92e by modulating stress-related cellular responses, impacting its function during cellular stress conditions. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
CHK1 kinase inhibitor, impacting cell cycle checkpoints. By modulating CHK1 activity, it indirectly regulates C6orf106_D17Wsu92e, influencing processes linked to its function during cell cycle progression. | ||||||